BACKGROUND: The optimal sequencing of antiretroviral regimens for the treatment of infection with human immunodeficiency virus type 1 (HIV-1) is unknown. We compared several different antiretroviral treatment strategies. METHODS: This multicenter, randomized, partially double-blind trial used a factorial design to compare pairs of sequential three-drug regimens, starting with a regimen including zidovudine and lamivudine or a regimen including didanosine and stavudine in combination with either nelfinavir or efavirenz. The primary end point was the length of time to the failure of the second three-drug regimen. RESULTS: A total of 620 subjects who had not previously received antiretroviral therapy were followed for a median of 2.3 years. Starting with a three-drug regimen containing efavirenz combined with zidovudine and lamivudine (but not efavirenz combined with didanosine and stavudine) appeared to delay the failure of the second regimen, as compared with starting with a regimen containing nelfinavir (hazard ratio for failure of the second regimen, 0.71; 95 percent confidence interval, 0.48 to 1.06), as well as to delay the second virologic failure (hazard ratio, 0.56; 95 percent confidence interval, 0.29 to 1.09), and significantly delayed the failure of the first regimen (hazard ratio, 0.39) and the first virologic failure (hazard ratio, 0.34). Starting with zidovudine and lamivudine combined with efavirenz (but not zidovudine and lamivudine combined with nelfinavir) appeared to delay the failure of the second regimen, as compared with starting with didanosine and stavudine (hazard ratio, 0.68), and significantly delayed both the first and the second virologic failures (hazard ratio for the first virologic failure, 0.39; hazard ratio for the second virologic failure, 0.47), as well as the failure of the first regimen (hazard ratio, 0.35). The initial use of zidovudine, lamivudine, and efavirenz resulted in a shorter time to viral suppression. CONCLUSIONS: The efficacy of antiretroviral drugs depends on how they are combined. The combination of zidovudine, lamivudine, and efavirenz is superior to the other antiretroviral regimens used as initial therapy in this study. Copyright 2003 Massachusetts Medical Society
RCT Entities:
BACKGROUND: The optimal sequencing of antiretroviral regimens for the treatment of infection with human immunodeficiency virus type 1 (HIV-1) is unknown. We compared several different antiretroviral treatment strategies. METHODS: This multicenter, randomized, partially double-blind trial used a factorial design to compare pairs of sequential three-drug regimens, starting with a regimen including zidovudine and lamivudine or a regimen including didanosine and stavudine in combination with either nelfinavir or efavirenz. The primary end point was the length of time to the failure of the second three-drug regimen. RESULTS: A total of 620 subjects who had not previously received antiretroviral therapy were followed for a median of 2.3 years. Starting with a three-drug regimen containing efavirenz combined with zidovudine and lamivudine (but not efavirenz combined with didanosine and stavudine) appeared to delay the failure of the second regimen, as compared with starting with a regimen containing nelfinavir (hazard ratio for failure of the second regimen, 0.71; 95 percent confidence interval, 0.48 to 1.06), as well as to delay the second virologic failure (hazard ratio, 0.56; 95 percent confidence interval, 0.29 to 1.09), and significantly delayed the failure of the first regimen (hazard ratio, 0.39) and the first virologic failure (hazard ratio, 0.34). Starting with zidovudine and lamivudine combined with efavirenz (but not zidovudine and lamivudine combined with nelfinavir) appeared to delay the failure of the second regimen, as compared with starting with didanosine and stavudine (hazard ratio, 0.68), and significantly delayed both the first and the second virologic failures (hazard ratio for the first virologic failure, 0.39; hazard ratio for the second virologic failure, 0.47), as well as the failure of the first regimen (hazard ratio, 0.35). The initial use of zidovudine, lamivudine, and efavirenz resulted in a shorter time to viral suppression. CONCLUSIONS: The efficacy of antiretroviral drugs depends on how they are combined. The combination of zidovudine, lamivudine, and efavirenz is superior to the other antiretroviral regimens used as initial therapy in this study. Copyright 2003 Massachusetts Medical Society
Authors: S Grabar; C Pradier; E Le Corfec; R Lancar; C Allavena; M Bentata; P Berlureau; C Dupont; P Fabbro-Peray; I Poizot-Martin; D Costagliola Journal: AIDS Date: 2000-01-28 Impact factor: 4.177
Authors: D V Havlir; N S Hellmann; C J Petropoulos; J M Whitcomb; A C Collier; M S Hirsch; P Tebas; J P Sommadossi; D D Richman Journal: JAMA Date: 2000-01-12 Impact factor: 56.272
Authors: R Paredes; A Mocroft; O Kirk; A Lazzarin; S E Barton; J van Lunzen; T L Katzenstein; F Antunes; J D Lundgren; B Clotet Journal: Arch Intern Med Date: 2000-04-24
Authors: L Bacheler; S Jeffrey; G Hanna; R D'Aquila; L Wallace; K Logue; B Cordova; K Hertogs; B Larder; R Buckery; D Baker; K Gallagher; H Scarnati; R Tritch; C Rizzo Journal: J Virol Date: 2001-06 Impact factor: 5.103
Authors: Hélène C F Côté; Zabrina L Brumme; Kevin J P Craib; Christopher S Alexander; Brian Wynhoven; Lillian Ting; Hubert Wong; Marianne Harris; P Richard Harrigan; Michael V O'Shaughnessy; Julio S G Montaner Journal: N Engl J Med Date: 2002-03-14 Impact factor: 91.245
Authors: R L Murphy; R M Gulick; V DeGruttola; R T D'Aquila; J J Eron; J P Sommadossi; J S Currier; L Smeaton; I Frank; A M Caliendo; J G Gerber; R Tung; D R Kuritzkes Journal: J Infect Dis Date: 1999-04 Impact factor: 5.226
Authors: Jeonnette R Ickovics; Ann Cameron; Robert Zackin; Roland Bassett; Margaret Chesney; Victoria A Johnson; Daniel R Kuritzkes Journal: Antivir Ther Date: 2002-09
Authors: Henry Sunpath; Baohua Wu; Michelle Gordon; Jane Hampton; Brent Johnson; Mahomed-Yunus S Moosa; Claudia Ordonez; Daniel R Kuritzkes; Vincent C Marconi Journal: AIDS Date: 2012-08-24 Impact factor: 4.177
Authors: C William Wester; Ori M Stitelman; Victor deGruttola; Hermann Bussmann; Richard G Marlink; Mark J van der Laan Journal: AIDS Res Hum Retroviruses Date: 2012-03-23 Impact factor: 2.205
Authors: Judith J Lok; Peter W Hunt; Ann C Collier; Constance A Benson; Mallory D Witt; Amneris E Luque; Steven G Deeks; Ronald J Bosch Journal: AIDS Date: 2013-08-24 Impact factor: 4.177
Authors: Heather J Ribaudo; Kimberly Y Smith; Gregory K Robbins; Charles Flexner; Richard Haubrich; Yun Chen; Margaret A Fischl; Bruce R Schackman; Sharon A Riddler; Roy M Gulick Journal: Clin Infect Dis Date: 2013-09-17 Impact factor: 9.079
Authors: Bruce R Schackman; Callie A Scott; Paul E Sax; Elena Losina; Timothy J Wilkin; John E McKinnon; Susan Swindells; Milton C Weinstein; Kenneth A Freedberg Journal: Clin Infect Dis Date: 2007-09-04 Impact factor: 9.079